GlaxoSmithKline has been experiencing a high demand for its meningitis B vaccine Bexsero that has led to a shortage of doses for U.K. private clinics outside of the country's National Health Service.
After struggling out of the gate with Novartis' vaccines in hand, GlaxoSmithKline's vaccines unit turned its fortune in the third quarter and was able to deliver considerable increases in sales and profits.
The British Joint Committee on Vaccination and Immunisation recommended that a meningitis B jab be added to the routine childhood vaccination schedule. But thanks to pricing negotiations, the administration of GlaxoSmithKline's--formerly Novartis'--Bexsero to babies aged two months, four months and 12-13 months began just this week.
It's been 7 months since price negotiations over meningitis B vaccine Bexsero began between Novartis and the U.K. government. And as far as new owner GlaxoSmithKline is concerned, that's long enough.
Novartis may have spent 7 months negotiating fruitlessly with the U.K. government over the price of meningitis B vaccine Bexsero, but now that the product is in GlaxoSmithKline's hands, its new owner intends to do no such thing.
GlaxoSmithKline and Novartis have finally closed the multibillion-dollar asset swap that's sending GSK's oncology portfolio to Switzerland in exchange for most of the latter's vaccines unit. Now, all eyes will be on the British pharma giant, who industry watchers agree has more to prove after exiting the fast-growing cancer field.
Pfizer and Novartis have snagged a nod from the CDC's Advisory Committee on Immunization Practices for their recently approved meningitis B vaccines. There's just one problem: It doesn't cover nearly as large a population as the pharma giants would like.
Pfizer and Novartis officially have a nod from the CDC's Advisory Committee on Immunization Practices (ACIP) for their recently approved meningitis B vaccines. Problem is, it doesn't cover nearly as large a population as the pharma giants would like.
After years of pinning its vaccine ambitions on meningitis B shot Bexsero, Novartis' FDA approval is here. But as it prepares to fork over the jab--along with the bulk of its vaccines business--to deal partner GlaxoSmithKline, there are other hurdles in the way of its success--including some new competition from Pfizer.
Novartis has long pinned its hopes on meningitis B shot Bexsero to revitalize its lagging vaccines unit. Now, the company is celebrating the product's FDA approval, even as it prepares to hand off the jab to GlaxoSmithKline in a blockbuster asset swap.